Volrustomig NSCLC Futility: Dual Checkpoint Bispecific Fails Against Pembrolizumab-Chemo Standard

AstraZeneca Halts Phase 3 Lung Cancer Trial for Bispecific Volrustomig

AstraZeneca has terminated a Phase 3 study of its experimental bispecific antibody drug, volrustomig, for non-small cell lung cancer (NSCLC). An interim data check by trial monitors concluded the therapy was unlikely to improve survival compared to standard treatment, which involved Merck & Co.’s Keytruda and chemotherapy. Volrustomig, designed to block both PD-L1 and CTLA-4 immune checkpoints, was a key asset in AstraZeneca's strategy to achieve $80 billion in sales by 2030. Despite this setback in lung cancer, the company plans to continue other Phase 3 trials for volrustomig in mesothelioma, cervical, and head and neck cancers.

• AstraZeneca's decision to terminate the Phase 3 trial for volrustomig in lung cancer was based on an interim data analysis. Trial data monitors determined that the experimental bispecific antibody was unlikely to meet its primary survival goals, indicating a lack of significant benefit over the comparator arm of Keytruda plus chemotherapy.
• Volrustomig is a bispecific antibody designed to target and block both PD-L1 and CTLA-4 immune checkpoints simultaneously. This approach aimed to improve upon existing immunotherapies like PD-1/PD-L1 blockers (e.g., Keytruda) and CTLA-4 blockers (e.g., Yervoy), which have shown efficacy individually or in combination, by offering a single-agent dual blockade.
• The termination of this lung cancer trial is a setback for AstraZeneca's ambitious $80 billion sales target by 2030, as volrustomig was a significant part of its experimental pipeline. The drug has previously faced scrutiny regarding its safety profile, with one-third of participants in its first human trial discontinuing treatment due to side effects, raising questions about its therapeutic window.

Safety Challenges for Volrustomig in Lung Cancer Development

Volrustomig's safety and tolerability profile has been characterized in a first-in-human phase I study (NCT03530397), enrolling 86 patients with advanced cancer who received volrustomig at doses ranging from 2.25 to 2,500 mg intravenously every three weeks. The majority of the study population (90.7%) was immunotherapy-naïve, providing a relevant baseline for interpreting immune-related adverse event patterns.

• Immune-mediated toxicities dominated the TRAE profile, with pruritus (30.2%), hypothyroidism (26.7%), hyperthyroidism (24.4%), and rash (24.4%) among the most frequently reported treatment-related adverse events — a pattern consistent with dual PD-1/CTLA-4 checkpoint inhibition.

• Treatment discontinuation due to TRAEs was notable, occurring in 33.7% of patients, signaling a meaningful tolerability burden that will require careful management strategy design in ongoing and future trials.

• One treatment-related death was reported during the study, underscoring the need for rigorous safety monitoring protocols as volrustomig advances into broader patient populations.

• The dose-exploration phase successfully characterized the tolerable dose range across the 2.25–2,500 mg spectrum, with evaluation of dose-limiting toxicities and maximum tolerated dose as primary objectives, providing the pharmacological basis for dose selection in phase III programs.

• The overall safety profile was considered compatible with continued clinical development, with phase III trials now underway evaluating volrustomig both as monotherapy and within combination regimens.

The Competitive Landscape for PD-L1/CTLA-4 Bispecifics in NSCLC

The PD-1/CTLA-4 bispecific antibody class is an actively investigated therapeutic space, with multiple agents advancing through clinical development across solid tumor indications. Cadonilimab represents a notable comparator to volrustomig, sharing the same dual checkpoint blockade mechanism of action and having demonstrated clinical activity across several advanced solid tumors.

Bispecific Setback: A Reality Check for Novel Immunotherapies in NSCLC

The recent decision by AstraZeneca to halt its Phase 3 study of volrustomig in non-small cell lung cancer (NSCLC) marks a pivotal moment for the company and the broader immunotherapy landscape. Volrustomig, a novel bispecific antibody targeting both PD-L1 and CTLA-4, was positioned as a key growth driver. However, an interim analysis concluded it was unlikely to improve survival compared to the current standard of care, which includes pembrolizumab (Keytruda) and chemotherapy.

This outcome underscores the formidable challenge of innovating in a space already dominated by highly effective immune checkpoint inhibitors. Research consistently shows that anti-PD-1/PD-L1 therapies have significantly improved outcomes for advanced NSCLC patients, particularly when combined with chemotherapy or in patients with high PD-L1 expression. While early-phase data for volrustomig indicated robust peripheral and intra-tumoral T cell activation and some objective responses, this promise did not translate into a survival benefit in the larger Phase 3 setting against an established, potent regimen.

For AstraZeneca, this represents a significant setback to its ambitious sales targets, necessitating a strategic re-evaluation of its oncology pipeline. The company will now likely place greater emphasis on volrustomig's ongoing Phase 3 trials in other indications, such as mesothelioma, cervical, and head and neck cancers. However, the high rate of treatment-related adverse events and discontinuations observed in earlier studies, coupled with the NSCLC futility, raises questions about the drug's overall risk-benefit profile and its potential for broad applicability.

This event also serves as a broader lesson for immunotherapy development. Simply combining two known checkpoint targets, even in a bispecific format, may not be sufficient to surpass the efficacy of optimized existing therapies. Future success in this competitive arena will likely hinge on:

• More precise patient selection through advanced biomarker strategies.

• Novel mechanisms of action that address resistance pathways.

• Demonstrating clear, differentiated efficacy and safety profiles against increasingly effective standard-of-care regimens.

The NSCLC market remains a high-bar environment, and this outcome reinforces the strong position of current market leaders while challenging developers to innovate with even greater precision.